![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, July 19, 2013 9:27:11 AM
The important and rate-determining step towards the start of any clinical program for FluCide is the construction of the production plant in Connecticut
o NNVC hired contractors and builders who build the framework at their own plants, then deliver to site in a modular fashion and then integrate on-site
o This ex-location production is both cost- and time- efficient and could be completed 5 months from start date
Lets be conservative and say that assembly begins on this month, July 2013. NNVC should have the plant ready by December2013!...ready and validated.
o The pilot plant will likely be ready to begin producing FluCide test batches by YE2013 or 1Q2014
Indication from NNVC - FDA meeting is: toxicology studies will continue in parallel with the construction of the manufacturing plants. Both will likely conclude at the same time by YE2013 allowing for production of drug materials for the seamless start of the clinical program in 2014.
Puffer indicated that to be conservative, human trials are likely to start Q3 2014. From my perspective, conservative is good.
In the NNVC RedChip video Dr. Seymour indicated NNVC is on a path, a track, Project Managers are steering, key activities on a timeline, to completion. That video, and the demeanor of Dr. Seymour fills many voids in the big picture. It was good.
The potential of catastrophic event(s) that could delay are always present but the Project Management group steering is a seasoned one. The plant will be physically complete by the end of 2013 and the steady climb will begin.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM